Costs Associated with Adverse Drug Reactions Among HIV/TB Patients in Thailand

References

• World Health Organiztion. HIV/AIDS; 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/hiv-aids. Accessed December 6, 2021.
   Google Scholar
• World Health Organiztion. Global tuberculosis report 2021; 2021. Available from: https://www.who.int/publications/digital/global-tuberculosis-report-2021. Accessed January 31, 2022.
   Google Scholar
• Centers for Disease Control and Prevention. Global HIV and TB; 2021. Available from: https://www.cdc.gov/globalhivtb/index.html. Accessed April 20, 2021.
   Google Scholar
• Avert. HIV and AIDS in Thailand; 2020. Available from: https://www.avert.org/professionals/hiv-around-world/asia-pacific/thailand. Accessed August 5, 2021.
   Google Scholar
• United Nations Programme on HIV/AIDS. Thailand country data 2020; 2020. Available from: https://www.aidsdatahub.org/resource/thailand-country-data-2020. Accessed January 31, 2022.
   Google Scholar
• Ministry of Public Health. Tuberculosis profile: Thailand; 2021. Available from: https://www.tbthailand.org/statustb.html. Accessed January 31, 2022.
   Google Scholar
• Bureau of AIDS, Tuberculosis and Sexually Transmitted Infections, Department of Disease Control, Ministry of Public Health. Thailand national guidelines on HIV/AIDS diagnosis, treatment and prevention 2020/2021. Bangkok: Aksorn graphic and design publishing limited partnership; 2019.
   Google Scholar
• Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV; 2022. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/guidelines-adult-adolescent-arv.pdf. Accessed April 24, 2022.
   Google Scholar
• Division of Tuberculosis, Ministry of Public Health. National tuberculosis control programme guideline, Thailand 2021. Bangkok: Aksorn graphic and design publishing limited partnership; 2021.
   Google Scholar
• Nahid P, Dorman SE, Alipanah N, et al. Executive summary: official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):853–867. doi:10.1093/cid/ciw566
   PubMed Web of Science ®Google Scholar
• Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255–1259. doi:10.1016/S0140-6736(00)02799-9
   PubMed Web of Science ®Google Scholar
• Sultana J, Cutroneo P, Trifirò G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl 1):S73–S77. doi:10.4103/0976-500X.120957
   PubMedGoogle Scholar
• Giardina C, Cutroneo PM, Mocciaro E, et al. Adverse drug reactions in hospitalized patients: results of the FORWARD (Facilitation of Reporting in Hospital Ward) study. Front Pharmacol. 2018;9. doi:10.3389/fphar.2018.00350
   PubMed Web of Science ®Google Scholar
• Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006;5(2):231–249. doi:10.1517/14740338.5.2.231
   PubMed Web of Science ®Google Scholar
• NIH’s Office of AIDS Research. Adverse effects of antiretroviral agents; 2021. Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/adverse-effects-antiretroviral-agents. Accessed June 3, 2021.
   Google Scholar
• Insani WN, Whittlesea C, Alwafi H, et al. Prevalence of adverse drug reactions in the primary care setting: a systematic review and meta-analysis. PLoS One. 2021;16(5):e0252161. doi:10.1371/journal.pone.0252161
   PubMed Web of Science ®Google Scholar
• Teo YX, Walsh SA. Severe adverse drug reactions. Clin Med. 2016;16(1):79–83. doi:10.7861/clinmedicine.16-1-79
   PubMed Web of Science ®Google Scholar
• Dadebo F, Wiafe E, Padayachee N, et al. Antiretroviral-related adverse reactions: a cause for concern. Sys Rev Pharm. 2021;12(9):684–690.
   Google Scholar
• Peter J, Choshi P, Lehloenya RJ. Drug hypersensitivity in HIV infection. Curr Opin Allergy Clin Immunol. 2019;19(4):272–282. doi:10.1097/ACI.0000000000000545
   PubMed Web of Science ®Google Scholar
• Montessori V, Press N, Harris M, et al. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170(2):229–238.
   PubMed Web of Science ®Google Scholar
• Tadesse WT, Mekonnen AB, Tesfaye WH, Tadesse YT. Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study. BMC Pharmacol Toxicol. 2014;15(1):32. doi:10.1186/2050-6511-15-32
   PubMed Web of Science ®Google Scholar
• Rajesh R, Sudha V, Varma D, Sonika S. Association between medication adherence outcomes and adverse drug reactions to highly active antiretroviral therapy in Indian human immunodeficiency virus-positive patients. J Young Pharm. 2012;4(4):250–260. doi:10.4103/0975-1483.104369
   PubMedGoogle Scholar
• Bea S, Lee H, Kim J, et al. Adherence and associated factors of treatment regimen in drug-susceptible tuberculosis patients. Front Pharmacol. 2021;12. doi:10.3389/fphar.2021.625078
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen H, Huang Z, et al. Drug non-adherence and reasons among multidrug-resistant tuberculosis patients In Guizhou, China: a cross-sectional study. Patient Prefer Adherence. 2019;13:1641–1653. doi:10.2147/PPA.S219920
   PubMed Web of Science ®Google Scholar
• Chaiyanukit N. Operating cost of adverse drug reaction of antituberculosis drugs at regional tuberculosis center 10 Chiang Mai [dissertation]. Chiang Mai: Public Health, Chiang Mai University; 2001.
   Google Scholar
• Srimongkol P. Cost analysis of adverse drug reactions and effectiveness in people living with HIV/AIDS receiving GPO-Vir S or GPO-Vir Z at Nakornping Hospital, Chiang Mai Province [dissertation]. Chiang Mai: Pharmacy, Chaing Mai University; 2009.
   Google Scholar
• Rajesh R, Vidyasagar S, Varma D, et al. Evaluation of direct cost of adverse drug reactions to highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients. JCRHAP. 2012;1(1):12–21. doi:10.14302/issn.2324-7339.jcrhap-12-71
   Google Scholar
• Dekoven M, Makin C, Slaff S, et al. Economic burden of HIV antiretroviral therapy adverse events in the United States. J Int Assoc Provid AIDS Care. 2015;15(1):66–76. doi:10.1177/2325957415594883
   PubMedGoogle Scholar
• Schnippel K, Firnhaber C, Berhanu R, et al. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa. Int J Tuberc Lung Dis. 2018;22(4):393–398. doi:10.5588/ijtld.17.0661
   PubMed Web of Science ®Google Scholar
• Gyllensten H, Rehnberg C, Jönsson AK, et al. Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey. BMJ Open. 2013;3(6):e002574. doi:10.1136/bmjopen-2013-002574
   PubMed Web of Science ®Google Scholar
• Gyllensten H, Hakkarainen KM, Hägg S, et al. Economic impact of adverse drug events–a retrospective population-based cohort study of 4970 adults. PLoS One. 2014;9(3):e92061. doi:10.1371/journal.pone.0092061
   PubMed Web of Science ®Google Scholar
• Naranjo C, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.154
   PubMed Web of Science ®Google Scholar
• Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49(9):2229–2232.
   PubMedGoogle Scholar
• Lemeshow S, Hosmer DW Jr., Klar J, Lwanga SK. Adequacy of Sample Size in Health Studies. Chichester: John Wiley & Sons Ltd; 1990.
   Google Scholar
• Nuntasaen T, Soontornpas R, Mootsikapan P, Soontornpas C. Management of adverse reaction in patients with HIV-infection at a university hospital of Thailand. IJPS. 2016;12:29–33.
   Google Scholar
• Thongrayng W, Kasinwat N, Limcharoen N, Nooratkaew K. Adverse reactions during the use of anti-tuberculosis drugs and treatment failure. Thai Pharm Health Sci J. 2008;4(1):46–51.
   Google Scholar
• Drug and Medical Supply Information, Ministry of Public Health. Drug and medical supply reference price; 2021. Available from: http://dmsic.moph.go.th/#. Accessed April 4, 2021.
   Google Scholar
• Riewpaiboon A. Standard cost lists for health economic evaluation in Thailand. J Med Assoc Thai. 2014;97(Suppl 5):S127–134.
   PubMedGoogle Scholar
• Office of the national economic and social development board. National Income of Thailand 2020; 2021. Available from: https://www.nesdc.go.th/nesdb_en/more_news.php?cid=154&filename=national_account. Accessed June 21, 2021.
   Google Scholar
• Bureau of Trade and Economic Indices. Report for consumer price index of Thailand year 2021; 2021. Available from: http://www.price.moc.go.th/price/cpi/index_new_all.asp. Accessed June 20, 2021.
   Google Scholar
• Bank of Thailand. Rates of exchange of commercial banks in Bangkok metropolis; 2021. Available from: https://www.bot.or.th/App/BTWS_STAT/statistics/ReportPage.aspx?reportID=123&language=eng. Accessed July 21, 2021.
   Google Scholar
• Mudbouch N. Antiretroviral therapy: the incidence of the adverse drug reaction (ADR) among HIV infected adult patients. SCNJ. 2014;1(2):1–16.
   Google Scholar
• Thongraung W, Kasinwat N, Limcharoen N, Nuratkaew K. Adverse reactions during using antituberculosis drugs and treatment failure. Thai Pharm Health Sci J. 2008;4(1):46–51.
   Google Scholar
• Imam F, Sharma M, Khayyam KU, et al. Adverse drug reaction prevalence and mechanisms of action of first-line anti-tubercular drugs. Saudi Pharm J. 2020;28(3):316–324. doi:10.1016/j.jsps.2020.01.011
   PubMed Web of Science ®Google Scholar
• Thontham A, Polsook R. Symptom experience of adverse drug reaction among male and female patients with newly diagnosed pulmonary tuberculosis in Thailand. BNJ. 2021;7(3):195–202. doi:10.33546/bnj.1337
   Web of Science ®Google Scholar
• Suh DC, Woodall B, Shin S, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother. 2000;34(12):1373–1379. doi:10.1345/aph.10094
   PubMed Web of Science ®Google Scholar
• Bordet R, Gautier S, Le Louet H, et al. Analysis of the direct cost of adverse drug reactions in hospitalised patients. Eur J Clin Pharmacol. 2001;56(12):935–941. doi:10.1007/s002280000260
   PubMed Web of Science ®Google Scholar
• Strategy and planning division of Office of the Permanent Secretary Ministry of Public Health. Summary of illness report 2020; 2021. Available from: https://bps.moph.go.th/new_bps/sites/default/files/ill_2020_full_27092021%20v2.pdf. Accessed January 25, 2022.
   Google Scholar
• Yang MS, Kim JY, Kang MG, et al. Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea. Korean J Intern Med. 2019;34(1):195–201. doi:10.3904/kjim.2015.365
   PubMed Web of Science ®Google Scholar
• Formica D, Sultana J, Cutroneo PM, et al. The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opin Drug Saf. 2018;17(7):681–695. doi:10.1080/14740338.2018.1491547
   PubMed Web of Science ®Google Scholar
• Homar F, Lozano V, Martínez-Gómez J, et al. Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs. Health Econ Rev. 2012;2(1):16. doi:10.1186/2191-1991-2-16
   PubMedGoogle Scholar
• Simpson KN, Chen SY, Wu AW, et al. Costs of adverse events among patients with HIV infection treated with nonnucleoside reverse transcriptase inhibitors. HIV Med. 2014;15(8):488–498. doi:10.1111/hiv.12145
   PubMed Web of Science ®Google Scholar